Axcella Announces Alison D. Schecter, M.D., as President of R&D
Experienced biopharma leader to oversee research, candidate development, clinical and regulatory functions CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella (Nasdaq:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced the appointment of Alison D. Schecter, M.D., as the company’s President of Research and Development. In this role, Dr. Schecter will oversee all of the company’s research, product candidate design, clinical and regulatory efforts. Additionally, Ma...
Source: pharmiweb.com